JP2019511553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511553A5 JP2019511553A5 JP2018554360A JP2018554360A JP2019511553A5 JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5 JP 2018554360 A JP2018554360 A JP 2018554360A JP 2018554360 A JP2018554360 A JP 2018554360A JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- inhibitor
- composition according
- dyrk1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323583P | 2016-04-15 | 2016-04-15 | |
| US62/323,583 | 2016-04-15 | ||
| PCT/US2017/027734 WO2017181087A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511553A JP2019511553A (ja) | 2019-04-25 |
| JP2019511553A5 true JP2019511553A5 (enExample) | 2020-06-11 |
| JP7278776B2 JP7278776B2 (ja) | 2023-05-22 |
Family
ID=60039311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554360A Active JP7278776B2 (ja) | 2016-04-15 | 2017-04-14 | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10314843B2 (enExample) |
| EP (1) | EP3443351A4 (enExample) |
| JP (1) | JP7278776B2 (enExample) |
| KR (2) | KR20230020560A (enExample) |
| CN (1) | CN109313197A (enExample) |
| AU (2) | AU2017248807A1 (enExample) |
| BR (1) | BR112018071023A2 (enExample) |
| CA (1) | CA3020978A1 (enExample) |
| IL (2) | IL292475A (enExample) |
| MX (2) | MX2018012508A (enExample) |
| WO (1) | WO2017181087A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012511A (es) | 2016-04-15 | 2019-07-08 | Felicitex Therapeutics Inc | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598758A (en) * | 2009-09-11 | 2013-12-20 | Amgen Inc | N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| DK2744797T3 (en) * | 2011-08-19 | 2015-10-19 | Diaxonhit | Dyrk1-inhibitors and uses thereof |
| FR2993317B1 (fr) | 2012-07-16 | 2014-08-15 | Snecma | Carter de turbomachine dans un materiau composite et procede de fabrication associe |
| JP2015534584A (ja) | 2012-10-10 | 2015-12-03 | フェリシテックス・セラピューティクス，インコーポレイテッド | 静止癌細胞の標的化による癌の治療 |
| MA38656A1 (fr) * | 2013-06-11 | 2018-05-31 | Bayer Pharma AG | Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| EP3119393A4 (en) * | 2014-03-20 | 2018-02-28 | Samumed, LLC | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| DK3324954T3 (da) * | 2015-07-23 | 2022-05-02 | Calgent Biotechnology Co Ltd | Aminonapthoquinonforbindelser og farmaceutisk sammensætning til blokering af et ubiquitination-proteasom-system ved sygdomme |
| MX2018012511A (es) | 2016-04-15 | 2019-07-08 | Felicitex Therapeutics Inc | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. |
-
2017
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/ko not_active Ceased
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/pt not_active Application Discontinuation
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en not_active Ceased
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en not_active Withdrawn
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/es unknown
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/zh active Pending
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/ko active Active
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/ja active Active
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/es unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en not_active Abandoned
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511553A5 (enExample) | ||
| IL292475A (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | |
| JP2019511554A5 (enExample) | ||
| JP2010526098A5 (enExample) | ||
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2010526097A5 (enExample) | ||
| MX372716B (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| JP2014176384A5 (enExample) | ||
| EA201490357A1 (ru) | Индазолы | |
| JP2021501208A5 (enExample) | ||
| MY155639A (en) | 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| AR037032A1 (es) | Benzoimidazoles | |
| NZ721617A (en) | Heterocyclic compounds | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| PE20130246A1 (es) | COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO | |
| EA201890094A1 (ru) | Производные полициклических амидов в качестве ингибиторов cdk9 | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| PH12017500564A1 (en) | Novel imidazopyridazine compounds and their use | |
| JP2015520770A5 (enExample) | ||
| CY1118559T1 (el) | 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak | |
| WO2018035346A8 (en) | KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| JP2018511643A5 (enExample) | ||
| CU23921B1 (es) | Nuevos derivados dihidroindolonas |